The type IIb SN 2008ax: the nature of the progenitor

A source coincident with the position of the type IIb supernova (SN) 2008ax is identified in pre-explosion Hubble Space Telescope (HST) Wide Field Planetary Camera 2 observations in three optical filters. We identify and constrain two possible progenitor systems: (i) a single massive star that lost most of its hydrogen envelope through radiatively driven mass-loss processes, prior to exploding as a helium-rich Wolf-Rayet star with a residual hydrogen envelope, and (ii) an interacting binary in a low-mass cluster producing a stripped progenitor. Late time, high-resolution observations along with detailed modelling of the SN will be required to reveal the true nature of this progenitor star.

Ruling out a massive asymptotic giant-branch star as the progenitor of supernova 2005cs

We calculate the predicted UBVRIJHK absolute magnitudes for models of supernova progenitors and apply the result to the case of supernova 2005cs. We agree with previous results that the initial mass of the star was low, around 6 to 8 M-circle dot. However, such stars are thought to go through a second dredge-up to become asymptotic giant branch (AGB) stars. We show that had this occurred to the progenitor of 2005cs it would have been observed in JHK pre-explosion images. The progenitor was not detected in these bands and therefore we conclude that it was not an AGB star. Furthermore, if some AGB stars do produce supernovae they will have a clear signature in pre-explosion near-infrared images. Electron-capture supernovae are thought to occur in AGB stars, hence the implication is that 2005cs was not an electron-capture supernova but was the collapse of an iron core.

DOMINO-AD protocol:donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT

Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD. Memantine is licensed for moderate to severe dementia in AD but is not recommended by the England and Wales National Institute for Health and Clinical Excellence. However, there is little evidence to guide clinicians as to what to prescribe as AD advances; in particular, what to do as the condition progresses from moderate to severe. Options include continuing cholinesterase inhibitors irrespective of decline, adding memantine to cholinesterase inhibitors, or prescribing memantine instead of cholinesterase inhibitors. The aim of this trial is to establish the most effective drug option for people with AD who are progressing from moderate to severe dementia despite treatment with donepezil.